Xue Cui1,2, Min Peng2, Honglei Chen1,*
Oncologie, Vol.24, No.4, pp. 665-678, 2022, DOI:10.32604/oncologie.2022.023641
Abstract The emergence of tumor immunotherapy, especially immune checkpoint inhibitors (ICIs), has brought new life to
cancer treatment, and ICIs can effectively treat various tumors. Among the immune anti-cancer therapies, PD-1 is
undoubtedly the hot target after CTLA-4, but due to the ineffectiveness of PD-1 in treating certain tumors,
researchers have shifted their focus to other combination targets, such as LAG-3, TIM3, IDO-1, etc. One of these
promising targets is LAG-3, a target with multiple clinical trials, which has increasingly shown to be an inhibitory
co-receptor that plays a vital role in autoimmunity, cancer immunity, and anti-infection immunity. Immune combination therapy… More >
Login
Register
